USFDA recommended suspension of Avandia sales in February, but no action was taken. Looks like Saudi Arabia is taking the lead on this one.
Don't bother trying to find this on Google Health, by the way...InteractMD.com readers hear it first!
WSJ today has the 2009 number on healthcare expenditures in the US: $2.4 trillion. They check it in t
Salt Lake City April 8 2009 -- Myriad Pharmaceuticals Inc. announced today that the FDA has approved an Investigational New Drug (IND) application to begin a Phase 1 clinical study with its Hsp90 inhibitor MPC-3100 for the treatment of cancer. The clinical development plan for MPC-3100 is designed to expedite the drug candidate through the clinical development path. The Phase 1 trial will assess the safety and pharmacokinetics profile of MPC-3100.